Innobiochips made a significant impact at Medfit 2025, affirming its position as a leader in innovation within the In Vitro Diagnostics (IVD) field.
As a Contributing Sponsor of the event, Innobiochips enjoyed outstanding visibility, leveraging this leading European partnering event to present Omnys, its cutting-edge technology poised to revolutionize transfusion and blood diagnostics.
With nearly 1,000 participants from 30 countries, MedFIT stands as a premier event in the MedTech, Diagnostics, and Digital Health sectors—an ideal platform for Innobiochips to highlight its latest breakthrough in blood transfusion diagnostics technology.
A Resounding Success for Omnys
Omnys, the latest innovation from Innobiochips, captivated attention during the event, drawing in over 100 industry professionals. The technology addresses critical challenges in the transfusion and blood diagnostic landscape, showcasing Innobiochips’ commitment to advancing precision medicine with High Definition Multiplex Diagnostic Solutions.
The presentation of Omnys technologies and performance has sparked considerable interest from key players across the biotech, medtech and diagnostics community. The positive reception underlined the technology’s potential to reshape the sector, solidifying Innobiochips’ reputation for groundbreaking solutions.
Omnys is based on breakthrough technologies that enable high-resolution testing of blood components: Standard ABO/D typing, Phenotyping, Extended phenotyping and IAT.
Omnys enables clinicians to perform multiplex testing with unmatched precision, reliability, and efficiency – using minimal sample volumes: a true advancement for transfusion compatibility and the sustainability of diagnostic solutions.
- Omnys automates blood sample characterization using just 4 to 6 wells, boosting lab productivity by 4 times compared to traditional 16-well methods.
- Omnys reduces infectious waste, plastic use, and transport costs, supporting sustainability goals and lowering operational expenses.
- Omnys provides expanded data and embedded controls at no extra cost, improving donor/patient compatibility without adding complexity
In addition to the public showcase, Innobiochips engaged in over 20 one-to-one meetings with investors and potential technology partners. These targeted discussions focused on strategic collaborations and securing investment to accelerate Omnys’ journey to market.
Innobiochips’ presence at Medfit 2025 not only strengthened its industry standing but also set the stage for Omnys’ commercialization.